Kaviarasan Kuppan

Dr. Kaviarasan Kuppan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
SRSharmila Rajendran
Sharmila Rajendran
SSShanmuganathan Seetharaman
Shanmuganathan Seetharaman
Arun DharmarajanArun Dharmarajan
Arun Dharmarajan
KKKaviarasan Kuppan
Kaviarasan Kuppan

20 July 2022 in Experimental Eye Research
Verified
Journal Article
Closed access
SRSharmila Rajendran
Sharmila Rajendran
SSShanmuganathan Seetharaman
Shanmuganathan Seetharaman
UVUmashankar Vetrivel
Umashankar Vetrivel
KKKaviarasan Kuppan
Kaviarasan Kuppan

Verified
Journal Article
Open access
PDF file
PKPriyanka Kannan
Priyanka Kannan
MKMadhana Priya Nanda Kumar
Madhana Priya Nanda Kumar
SNSidharth Kumar N
Sidharth Kumar N
VVVasundra Vasudevan
Vasundra Vasudevan
KKKaviarasan Kuppan
Kaviarasan Kuppan
MRMagesh Ramasamy
Magesh Ramasamy
Sanfilippo syndrome type B, also known as mucopolysaccharidosis type IIIB (MPS IIIB), is a rare autosomal recessive lysosomal storage disorder caused by mutations in the N-acetyl-α-D-glucosaminidase (NAGLU) gene, which encodes the enzyme α-N-acetylglucosaminidase. This enzyme is essential for degrading heparan sulfate. The deficiency leads to toxic accumulation within cells. To investigate the impact of NAGLU mutations, mutational data were retrieved from public databases including NCBI, UniProt, and HGMD. A total of 162 variants were evaluated using sequence-based prediction tools to identify deleterious mutations, followed by structure-based in silico analyses to assess changes in protein stability, biophysical properties, and ligand-binding potential. Among the analyzed mutations, the I154R variant was identified as the most deleterious, showing disease-associated characteristics, structural instability, and impaired functional properties. Molecular docking with N-acetylglucosamine (NAG) revealed binding affinities of −4.17 kcal/mol for the native protein and −3.97 kcal/mol for the I154R mutant, suggesting a retained yet slightly reduced binding potential. Molecular dynamics simulations supported these findings, indicating stable trajectories, favorable interaction profiles, and moderate flexibility for both complexes. These results enhance our understanding of NAGLU-related pathogenicity in MPS IIIB, contributing to improved health care strategies and offering a valuable foundation for future therapeutic developments targeting enzyme dysfunction in Sanfilippo syndrome type B.

23 March 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SKSandhya Krishnan
Sandhya Krishnan
SMShriraam Mahadevan
Shriraam Mahadevan
HSHanuman Prasad Sharma
Hanuman Prasad Sharma
UDUndurti Narasimha Das
Undurti Narasimha Das
KKKaviarasan Kuppan
Kaviarasan Kuppan
Low-grade systemic inflammation is seen in type 2 diabetes mellitus (T2DM), which is also considered the underlying mechanism for the occurrence of major complications observed in these patients. In developing countries like India, prediabetes/insulin resistance is often overlooked. Specialized pro-resolving mediators (SPMs) are a family of anti-inflammatory lipid molecules that are needed to resolve inflammation to maintain immune balance and prevent complications due to DM. Treg cells are a subset of CD4 + T cells that express IL-2 receptor alpha chain CD25 and FOXP3 transcription factor to maintain immune tolerance during diabetes. In this context, the role of resolvins in the regulatory function of Treg cells assumes significance in the prevention and management of diabetic complications. In the current review, we explore the functions of Tregs and resolvins and their potential implications in managing insulin resistance, obesity, and type 2 diabetes.